# Signals Article: Putative Target O95793 for Ebola Virus Therapeutic Development
Background
Ebola virus disease (EVD) is a severe and often fatal illness caused by the Ebola virus, which has led to significant outbreaks in Africa and poses a global health threat. The disease is characterized by high mortality rates and a range of symptoms, including fever, vomiting, diarrhea, and hemorrhagic manifestations. Despite the development of vaccines and some therapeutic options, there remains a critical need for effective treatments. A putative target candidate, O95793, has been identified through data-mining efforts, suggesting a potential role in the pathogenesis of Ebola virus and warranting further investigation.Data-mining rationale
The identification of O95793 as a putative target was derived from a comprehensive analysis of UniProt's reviewed human entries for "Ebola virus," cross-referenced against 24 microarray datasets available in the NCBI Gene Expression Omnibus (GEO). Notably, O95793 was found to appear in several expression-profiling studies; however, it lacks any registered Phase 1 or higher clinical program. This absence indicates an opportunity for further exploration of its therapeutic potential. Additionally, many of the GEO datasets utilized in this analysis predate the adoption of modern empirical-Bayes statistical methods, such as limma, suggesting that a re-analysis could yield more robust insights.Why prior analyses may have missed this
Prior analyses may have missed the significance of O95793 due to several factors. The datasets analyzed were generated using older statistical methodologies that may not have adequately controlled for multiple testing, potentially obscuring the identification of differentially expressed genes. Furthermore, the complex interplay between host immune responses and viral pathogenesis in EVD may have diluted the signal for specific targets in earlier studies. The absence of a clinical program for O95793 further suggests that its potential therapeutic role has not been fully explored in the context of Ebola virus infection.Reasoning for further validation
To validate the potential of O95793 as a therapeutic target for Ebola virus, the following experimental approaches are recommended: 1. **Re-analyze GEO Datasets**: Utilize the limma package with Benjamini-Hochberg false discovery rate (FDR) correction set to < 0.05 to re-analyze the matched GEO datasets, which may reveal more accurate differential expression results. 2. **Validate Differentially-Expressed Genes**: Conduct quantitative PCR (qPCR) validation of the top differentially expressed genes identified in the re-analysis using an independent cohort to confirm their relevance in EVD. 3. **Check Tissue Specificity**: Investigate the tissue specificity of O95793 expression using resources such as the Genotype-Tissue Expression (GTEx) project and the Human Protein Atlas to assess its potential as a therapeutic target. 4. **Pathway Context Analysis**: Employ STRING or OmniPath databases to explore the biological pathways associated with O95793, providing context for its role in Ebola virus pathogenesis. 5. **Assess Druggability**: If O95793 is validated as a relevant target, evaluate its druggability using databases such as DGIdb and ChEMBL to identify potential small molecules or compounds that could be developed into therapeutics.References
- UniProt: O95793
- UniProt: P46934
- UniProt: Q99816
- UniProt: Q9NNX6
- UniProt: P05161
- GEO Datasets: GDS:200180226, GDS:200210189, GDS:200188630, GDS:200162846, GDS:200122692